Five-Year Patient-Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer.
Journal
International journal of radiation oncology, biology, physics
ISSN: 1879-355X
Titre abrégé: Int J Radiat Oncol Biol Phys
Pays: United States
ID NLM: 7603616
Informations de publication
Date de publication:
15 Jul 2023
15 Jul 2023
Historique:
received:
06
07
2022
revised:
28
11
2022
accepted:
12
12
2022
pmc-release:
15
07
2024
medline:
26
6
2023
pubmed:
3
1
2023
entrez:
2
1
2023
Statut:
ppublish
Résumé
There is considerable interest in very short (ultrahypofractionated) radiation therapy regimens to treat prostate cancer based on potential radiobiological advantages, patient convenience, and resource allocation benefits. Our objective is to demonstrate that detectable changes in health-related quality of life measured by the bowel and urinary domains of the Expanded Prostate Cancer Index Composite (EPIC-50) were not substantially worse than baseline scores. NRG Oncology's RTOG 0938 is a nonblinded randomized phase 2 study of National Comprehensive Cancer Network low-risk prostate cancer in which each arm is compared with a historical control. Patients were randomized to 5 fractions (7.25 Gy in 2 week and a day [twice a week]) or 12 fractions (4.3Gy in 2.5 weeks [5 times a week]). Secondary objectives assessed patient-reported toxicity at 5 years using the EPIC. Chi-square tests were used to assess the proportion of patients with a deterioration from baseline of >5 points for bowel, >2 points for urinary, and >11 points for sexual score. The study enrolled 127 patients to 5 fractions (121 eligible) and 128 patients to 12 fractions (125 eligible). The median follow-up for all patients at the time of analysis was 5.38 years. The 5-year frequency for >5 point change in bowel score were 38.4% (P = .27) and 23.4% (P = 0.98) for 5 and 12 fractions, respectively. The 5-year frequencies for >2 point change in urinary score were 46.6% (P = .15) and 36.4% (P = .70) for 5 and 12 fractions, respectively. For 5 fractions, 49.3% (P = .007) of patients had a drop in 5-year EPIC-50 sexual score of ≥11 points; for 12 fractions, 54% (P < .001) of patients had a drop in 5-year EPIC-50 sexual score of ≥11 points. Disease-free survival at 5 years is 89.6% (95% CI: 84.0-95.2) in the 5-fraction arm and 92.3% (95% CI: 87.4-97.1) in the 12-fraction arm. There was no late grade 4 or 5 treatment-related urinary or bowel toxicity. This study confirms that, based on long-term changes in bowel and urinary domains and toxicity, the 5- and 12-fraction regimens are well tolerated. These ultrahypofractionated approaches need to be compared with current standard radiation therapy regimens.
Identifiants
pubmed: 36592721
pii: S0360-3016(22)03671-9
doi: 10.1016/j.ijrobp.2022.12.022
pmc: PMC10619484
mid: NIHMS1879729
pii:
doi:
Types de publication
Randomized Controlled Trial
Clinical Trial, Phase II
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
770-778Subventions
Organisme : NCI NIH HHS
ID : U10 CA180868
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA189867
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA180803
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180822
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA233339
Pays : United States
Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.
Références
J Clin Oncol. 2016 Jul 10;34(20):2325-32
pubmed: 27044935
Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1099-105
pubmed: 17336216
Cancer. 2017 May 1;123(9):1635-1642
pubmed: 28001303
N Engl J Med. 2008 Mar 20;358(12):1250-61
pubmed: 18354103
Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):965-74
pubmed: 16798415
Health Policy. 1996 Jul;37(1):53-72
pubmed: 10158943
Int J Radiat Oncol Biol Phys. 1986 Apr;12(4):687-91
pubmed: 3700173
Clin Oncol (R Coll Radiol). 2008 Dec;20(10):729-37
pubmed: 18838256
Radiother Oncol. 2013 Nov;109(2):217-21
pubmed: 24060175
Int J Radiat Oncol Biol Phys. 1998 Apr 1;41(1):135-8
pubmed: 9588928
Int J Radiat Oncol Biol Phys. 2003 Jan 1;55(1):194-203
pubmed: 12504054
Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):1093-104
pubmed: 12829147
Health Policy. 1990 Dec;16(3):199-208
pubmed: 10109801
Lancet Oncol. 2016 Aug;17(8):1047-1060
pubmed: 27339115
Lancet. 2019 Aug 3;394(10196):385-395
pubmed: 31227373
Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1043-8
pubmed: 18755555
Int J Radiat Oncol Biol Phys. 2002 Jan 1;52(1):6-13
pubmed: 11777617
Pract Radiat Oncol. 2018 Jan - Feb;8(1):40-47
pubmed: 29304991
Radiat Oncol. 2013 May 13;8:118
pubmed: 23668632
Int J Radiat Oncol Biol Phys. 2018 Oct 1;102(2):287-295
pubmed: 29913254
Radiat Oncol. 2014 Jun 26;9:148
pubmed: 24966110
J Chronic Dis. 1974 Sep;27(7-8):365-75
pubmed: 4612056
JAMA. 2005 Sep 14;294(10):1233-9
pubmed: 16160131
J Clin Oncol. 2007 Nov 10;25(32):5078-81
pubmed: 17991924
Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):1101-8
pubmed: 14575842
Radiother Oncol. 2015 Aug;116(2):179-84
pubmed: 26276528
J Clin Oncol. 2002 Jan 15;20(2):557-66
pubmed: 11786586
J Clin Oncol. 2017 Jun 10;35(17):1884-1890
pubmed: 28296582
Cancer. 2015 Jul 15;121(14):2422-30
pubmed: 25847819
Radiat Oncol. 2017 Jan 13;12(1):14
pubmed: 28086825
Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):67-74
pubmed: 17765406
Qual Life Res. 2002 May;11(3):273-82
pubmed: 12074264
Int J Radiat Oncol Biol Phys. 1999 Mar 15;43(5):1095-101
pubmed: 10192361